OPKO HEALTH, INC.
OPKO HEALTH, INC. (OPK): 15 pipeline candidates · 2 upcoming catalysts · ~64 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
63.6 months
D/E 0.54
Lead: Approved
15 candidates
2 upcoming, next in ~166d
1 buy · 0 sells (180d)
A transparent, data-derived signal for OPKO HEALTH, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.0B
Cash
$355.6M
Quarterly Burn
$19.3M
Runway
63.6 mo
Revenue
$124.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (15 candidates)
| Drug | Phase |
|---|---|
| ctap101 | Phase 3 |
| ebv vaccine | Phase 1 |
| mdx2001 | Phase 1/Phase 2 |
| mdx2003 | Phase 1/Phase 2 |
| mdx2004 | Phase 1 |
| mdx2301 | Phase 1 |
| mod-4023 | Phase 3 |
| mstar antibody | Preclinical |
| ngenla | Approved |
| opk-88006 | Phase 1/Phase 2 |
Showing 10 of 15 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
231
Total value held
$179.4M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 36,232,223 | $41.3M |
| vanguard capital management llc | 28,998,328 | $33.1M |
| vanguard portfolio management llc | 14,769,719 | $16.8M |
| geode capital management, llc | 11,301,501 | $12.9M |
| state street corp | 9,501,377 | $10.8M |
| goldman sachs group inc | 7,675,026 | $8.7M |
| northern trust corp | 3,619,346 | $4.1M |
| charles schwab investment management inc | 3,574,039 | $4.1M |
| vanguard fiduciary trust co | 2,742,017 | $3.1M |
| op asset management ltd | 2,204,508 | $2.7M |
Showing top 10 of 231 institutional holders of OPKO HEALTH, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in OPKO HEALTH, INC.'s pipeline?
OPKO HEALTH, INC. (OPK) has 15 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OPKO HEALTH, INC.'s lead drug candidate?
OPKO HEALTH, INC.'s most advanced tracked candidate is ctap101 (Phase 3) for CKD Stage 3; Chronic Kidney Disease stage3.
What is OPKO HEALTH, INC.'s next catalyst?
OPKO HEALTH, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of OPK-88006 in Healthy and Presumed" — expected December 1, 2026.
What is OPKO HEALTH, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OPKO HEALTH, INC. has approximately 63.6 months of cash runway.
What is OPKO HEALTH, INC.'s market capitalization?
OPKO HEALTH, INC.'s market capitalization is approximately $1.0B.
Get the full picture on OPKO HEALTH, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.